Navigation Links
Pharmasset to Present at JMP Securities Healthcare Conference
Date:10/1/2009

PRINCETON, N.J., Oct. 1 /PRNewswire-FirstCall/ -- Pharmasset, Inc. (Nasdaq: VRUS) announces management will present at the JMP Securities Healthcare Conference. The conference will be held at the New York Palace Hotel in New York City (October 5-6, 2009).

Schaefer Price, Pharmasset's President and Chief Executive Officer, will provide an overview of the company on Tuesday, October 6, 2009 at 1:30 PM (ET).

To access a simultaneous webcast of Mr. Price's overview via the internet, log on to the "Events & Presentations" section of the Investor Center on Pharmasset's website at http://investor.pharmasset.com/events.cfm . Please connect to the website at least ten minutes prior to the start of the presentation to ensure adequate time for a reliable connection and any software download that may be necessary for the webcast.

A replay of the webcast will be available on Pharmasset's website for thirty days following the conference. The investor presentation will be available for download in PDF format immediately following each presentation in the "Events & Presentations" section of the Investor Center on Pharmasset's website at http://investor.pharmasset.com/events.cfm .

About Pharmasset

Pharmasset is a clinical-stage pharmaceutical company committed to discovering, developing, and commercializing novel drugs to treat viral infections. Pharmasset's primary focus is on the development of oral therapeutics for the treatment of hepatitis C virus (HCV) and, secondarily, on the development of Racivir(TM) for the treatment of human immunodeficiency virus (HIV). Our research and development efforts focus on nucleoside/tide analogs, a class of compounds which act as alternative substrates for the viral polymerase thus inhibiting viral replication. We currently have three clinical-stage product candidates. RG7128, a nucleoside analog for chronic HCV infections, is in a Phase 2b clinical trial in combination with Pegasys® plus Copegus® and is also in INFORM studies, the first series of studies designed to assess the potential of combinations of small molecules without Pegasys® and Copegus® to treat chronic HCV. These clinical studies are being conducted through a strategic collaboration with Roche. Our other clinical stage candidates are PSI-7851, an unpartnered, next generation HCV nucleotide analog which has completed Phase 1 clinical studies, and Racivir, for the treatment of HIV, which has completed a Phase 2 clinical trial.

Pegasys(®) and Copegus(® )are registered trademarks of Roche.

    Contact
    Richard E. T. Smith, Ph.D.
    VP, Investor Relations and Corporate Communications
    richard.smith@pharmasset.com
    Office: +1 (609) 613-4181

Forward-Looking Statements

Pharmasset "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: Statements in this press release regarding our business that are not historical facts are "forward-looking statements" that involve risks and uncertainties, including, without limitation, the risk that adverse events could cause the cessation or delay of any of the ongoing or planned clinical trials and/or our development of our product candidates, the risk that the results of previously conducted studies involving our product candidates will not be repeated or observed in ongoing or future studies involving our product candidates, the risk that our collaboration with Roche will not continue or will not be successful and the risk that any one or more of our product candidates will not be successfully developed and commercialized. For a discussion of these risks and uncertainties, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section of our Annual Report on Form 10-K for the fiscal year ended September 30, 2008 and our Quarterly Report on Form 10-Q for the period ended June 30, 2009 filed with the Securities and Exchange Commission entitled "Risk Factors" and discussions of potential risks and uncertainties in our subsequent filings with the Securities and Exchange Commission.

SOURCE Pharmasset, Inc.


'/>"/>
SOURCE Pharmasset, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Pharmasset Reports Fiscal Third Quarter 2009 Financial Results
2. Pharmasset Nominates PSI-938 as a New Nucleotide Analog Inhibitor of Hepatitis C for Preclinical Development
3. Pharmasset Initiates Phase 1b Multiple Ascending Dose Clinical Trial of PSI-7851 in Chronic Hepatitis C Patients
4. Pharmasset to Present at Deutsche Bank Healthcare Conference
5. Pharmasset to Present at Two Upcoming Investor Conferences
6. Pharmasset to Present at Two Upcoming Investor Conferences
7. Pharmasset to Present at the 27th Annual JPMorgan Healthcare Conference
8. Pharmasset to Webcast an Investor Event from the AASLD Meeting
9. Pharmasset Reports Financial Results for Quarter Ended March 31, 2008
10. Pharmasset to Present at the Rodman & Renshaw Healthcare Conference on Tuesday, May 20th
11. Pharmasset Appoints Patrick T. Higgins as Executive Vice President, Marketing & Sales
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/17/2017)... ... 17, 2017 , ... The award-winning producers of the Innovations ... Council for Therapeutic Recreation Certification (NCTRC), slated to air nationwide, fourth quarter 2017. ... a non-profit, international organization dedicated to professional excellence for the protection of consumers ...
(Date:8/17/2017)... ... ... Georgia Urology, the largest urology practice in the Southeastern United ... in East Cobb (4800 Olde Towne Parkway, Suite 220, Marietta). , “Georgia ... Haber, Georgia Urology’s managing partner. “She brings a passionate, fresh perspective on general urology ...
(Date:8/17/2017)... ... 17, 2017 , ... The 2017 Integrated Delivery Network (IDN) ... interact with their GPO and supplier partners. This year, Winifred Hayes, RN, PhD, ... of Clinical Value Analytics, have been invited to present “Episode-based Reimbursement and the ...
(Date:8/17/2017)... ... ... In its just released 2018 Edition, The Best Lawyers in America named ... consecutive year that Hardiman and Mills have been honored and the seventh year in ... Care Law while Mills was recognized in the Administrative and Regulatory Law category. ...
(Date:8/17/2017)... Angeles, California (PRWEB) , ... August 17, 2017 , ... ... the number of South Korean men obtaining plastic surgery, largely influenced by the growing ... and beauty clinic Beverly Hills Physicians notes that standards of male appearance are changing ...
Breaking Medicine News(10 mins):
(Date:8/14/2017)... and PETACH TIKVAH, Israel , Aug. ... a leading developer of adult stem cell technologies for ... ending June 30, 2017. ... for our pivotal Phase 3 trial to investigate NurOwn ... President and Chief Executive Officer of BrainStorm. "We have ...
(Date:8/7/2017)... 7, 2017 Insightin Health, provider of ... and engagement, announced the selection of Michael ... Development, effective as of February 2017. In this role, ... strategy for our clients. Wood brings with him ... and business analytics within the healthcare industry. Wood ...
(Date:8/4/2017)... Aug. 4, 2017 The search for test ... a physician/patient consult has long been the goal of ... notable focus of the largest meeting of lab professionals ... healthcare market research firm Kalorama Information.  The firm said ... offerings or related supplies and software were at the ...
Breaking Medicine Technology: